Eugia Pharma

AUG 7, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Fosaprepitant Dimeglumine (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval action for a labeling change to fosaprepitant dimeglumine; does not contain clinical trial efficacy or safety data.

MAY 27, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Methotrexate (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval for methotrexate labeling update; regulatory action does not report clinical trial outcomes or efficacy data.

MAY 6, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Leuprolide Acetate (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval for leuprolide acetate labeling; regulatory action record, not a clinical trial, so efficacy and safety data are not reported here.

APR 28, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Tranexamic Acid (Labeling)

U.S. Food and Drug Administration

This is an FDA supplemental approval action for labeling of an existing drug; it does not report clinical trial outcomes or comparative efficacy data.